Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Maintains Status Quo On Compulsory Licensing Provisions; Indian, MNC Lobbies Welcome Moves To Keep Flexibility But Future Doubts Linger

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Lobby groups from both the Indian generics industry and multinational companies hailed a decision by the Indian government to maintain the status quo on legal provisions that determine the conditions needed to trigger a compulsory license for a drug. But both sides expressed apprehension on how the present set of norms will unfold, fearing that future investments or market opportunities may be at risk if wrong moves are made

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts